Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor
China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...
Allorion Therapeutics
Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization
Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...
Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development
Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised...